Table 3.

Adjusted changes in metabolic variables in women with endometrial hyperplasia who were or were not supplemented with vitamin D for 12 weeks

	Placebo group (n = 30)	Vitamin D group (n = 30)	P a
Vitamin D (ng/mL)	2.3 ± 1.5	11.6 ± 1.5	<0.001
FPG (mg/dL)	2.0 ± 1.2	-1.5 ± 1.2	0.04
Insulin (μIU/mL)	1.1 ± 0.5	-0.8 ± 0.5	0.006
HOMA-IR	0.3 ± 0.1	-0.2 ± 0.1	0.006
HOMA-B	3.4 ± 1.9	-1.8 ± 1.9	0.06
QUICKI	-0.007 ± 0.003	0.003 ± 0.003	0.009
Triglycerides (mg/dL)	4.8 ± 8.5	9.0 ± 8.5	0.72
VLDL-cholesterol (mg/dL)	1.0 ± 1.7	1.8 ± 1.7	0.72
Total cholesterol (mg/dL)	5.5 ± 4.2	4.4 ± 4.2	0.85
LDL-cholesterol (mg/dL)	3.3 ± 4.0	0.9 ± 4.0	0.67
HDL-cholesterol (mg/dL)	1.6 ± 1.0	1.4 ± 1.0	0.89
hs-CRP (μg/mL)	-0.2 ± 0.4	-1.7 ± 0.4	0.007
NO (μmol/L)	0.8 ± 0.6	1.1 ± 0.6	0.73
TAC (mmol/L)	10.0 ± 8.7	59.9 ± 8.7	<0.001
GSH (μmol/L)	-3.7 ± 12.8	33.6 ± 12.8	0.04
MDA (μmol/L)	0.02 ± 0.04	-0.07 ± 0.04	0.12

All values are means ± SEs. Values are adjusted for baseline values, age, and BMI at baseline

FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis model of assessment-estimated insulin resistance, HOMA-B homeostasis model of assessment-estimated b cell function, hs-CRP high-sensitivity C-reactive protein, MDA malondialdehyde, NO nitric oxide, QUICKI quantitative insulin sensitivity check index, TAC total antioxidant capacity

^aObtained from ANCOVA